EE652 Cost Effectiveness Analysis of Pembrolizumab for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.891
https://www.valueinhealthjournal.com/article/S1098-3015(22)03095-9/fulltext
Title :
EE652 Cost Effectiveness Analysis of Pembrolizumab for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03095-9&doi=10.1016/j.jval.2022.09.891
First page :
Section Title :
Open access? :
No
Section Order :
10436